Content area
Abstract
Patient involvement in clinical trial design can facilitate the recruitment and retention of participants as well as potentially increase the uptake of the tested intervention and the impact of the findings on patient outcomes. Despite these benefits, patients still have very limited involvement in designing and conducting trials in nephrology. Many trials do not address research questions and outcomes that are important to patients, including patient-reported outcomes that reflect how patients feel and function. This limitation can undermine the relevance, reliability and value of trial-based evidence for decision-making in clinical practice and health policy. However, efforts to involve patients with kidney disease are increasing across all stages of the trial process from priority setting, to study design (including selection of outcomes and approaches to improve participant recruitment and retention) and dissemination and implementation of the findings. Harnessing the patient voice in designing trials can ensure that efforts and resources are directed towards patient-centred trials that address the needs, concerns and priorities of patients living with kidney disease with the aim of achieving transformative improvements in care and outcomes.
Meaningful involvement of patients in clinical trial design could lead to improvements in participant recruitment and retention, the uptake of the tested intervention and the impact of the findings. Here, the authors discuss the involvement of patients at all stages of trial design.
Details
; Scholes-Robertson, Nicole 1 ; Hawley, Carmel 2 ; Viecelli, Andrea K. 2
; Carter, Simon A. 1 ; Levin, Adeera 3 ; Hemmelgarn, Brenda R. 4 ; Harris, Tess 5 ; Craig, Jonathan C. 6 1 The University of Sydney, Sydney School of Public Health, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The Children’s Hospital at Westmead, Centre for Kidney Research, Sydney, Australia (GRID:grid.413973.b) (ISNI:0000 0000 9690 854X)
2 Princess Alexandra Hospital, Department of Nephrology, Brisbane, Australia (GRID:grid.412744.0) (ISNI:0000 0004 0380 2017); University of Queensland, Australasian Kidney Trials Network, Centre for Health Services Research, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
3 University of British Columbia, Division of Nephrology, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
4 Faculty of Medicine and Dentistry at University of Alberta, Edmonton, Canada (GRID:grid.17089.37) (ISNI:0000 0001 2190 316X)
5 PKD International, London, United Kingdom (GRID:grid.17089.37)
6 Flinders University, College of Medicine and Public Health, Adelaide, Australia (GRID:grid.1014.4) (ISNI:0000 0004 0367 2697)





